Boston Scientific EVP exercises 50,000 options, sells 50,000 shares

Boston Scientific (BSX) reported an insider transaction by its EVP & Group President, Cardiology.

Accepted by SEC EDGAR 11/04/2025 - 04:15 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Boston Scientific (BSX) reported an insider transaction by its EVP & Group President, Cardiology. On 11/03/2025, the officer exercised 50,000 stock options at $26.15 and sold a total of 50,000 common shares in three trades at $100.7481 (3,600 shares), $99.7607 (16,928), and $99.1414 (29,472), pursuant to a pre-established Rule 10b5-1 plan adopted on February 27, 2025.

Following these transactions, the officer directly owns 178,342 shares and indirectly holds 5,234 shares through a child.

Insider Trade Summary

Exercise and Sale: 50,000 shares ($3.67M approx. pre-tax spread)

Exercise and Sale 5 txns

Insider Fitzgerald Joseph Michael

Role EVP & Group Pres, Cardiology

Sold 50,000 shs ($4.97M)

Approx. gross sale proceeds $4.97M

Approx. exercise cost $1.31M

Approx. pre-tax spread $3.67M

Share of Position Sold 21.9%

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	50,000	$0.00	$0.00
Exercise	Common Stock	50,000	$26.15	$1.31M
Sale	Common Stock	3,600	$100.7481	$363K
Sale	Common Stock	16,928	$99.7607	$1.69M
Sale	Common Stock	29,472	$99.1414	$2.92M
Holding	Common Stock	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 0 contracts (Direct); Common Stock — 178,342 shares (Direct); Common Stock — 5,234 shares (Indirect, By Child)

Holdings Before and After: Stock Option (Right to Buy), 50,000 to 0 contracts (Direct); Common Stock, 178,342 to 178,342 shares (Direct)

Other Insiders: 1 other insider reported open-market sales of this stock in the 30 days up to this filing.

Footnotes (6)

1. F1. The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 27, 2025.
2. F2. Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $100.72 to $100.80, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
3. F3. Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $99.59 to $100.53, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
4. F4. Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $98.57 to $99.54, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
5. F5. The reporting person disclaims beneficial ownership of the shares held by his child, and this report should not be deemed an admission that the reporting person is the beneficial owner of his child's shares for purposes of Section 16 or for any other purpose.
6. F6. Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on December 1, 2018, the first anniversary of the date of grant.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did BSX report on 11/03/2025?

An executive exercised 50,000 options at $26.15 and sold 50,000 shares across three trades.

What were the sale prices and share counts for the BSX insider trades?

Sales were at weighted averages of $100.7481 (3,600), $99.7607 (16,928), and $99.1414 (29,472).

Was the BSX insider sale under a Rule 10b5-1 plan?

Yes. The transactions were effected under a Rule 10b5-1 plan adopted on February 27, 2025.

What is the BSX executive’s direct share ownership after the trades?

Direct ownership is 178,342 shares after the reported transactions.

Does the BSX executive report any indirect holdings?

Yes, 5,234 shares are indirectly held by a child (beneficial ownership disclaimed).

What derivative security was exercised in the BSX Form 4?

A stock option to purchase 50,000 shares at an exercise price of $26.15.

Who is the reporting person’s role at BSX?

The reporting person is an Officer, titled EVP & Group President, Cardiology.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Fitzgerald Joseph Michael

(Last) (First) (Middle)

300 BOSTON SCIENTIFIC WAY

(Street)

MARLBOROUGH MA 01752-1234

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BOSTON SCIENTIFIC CORP [ BSX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & Group Pres, Cardiology

3. Date of Earliest Transaction (Month/Day/Year)
11/03/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/03/2025		M(1)		50,000	A	$26.15	228,342	D
Common Stock	11/03/2025		S(1)		3,600	D	$100.7481(2)	224,742	D
Common Stock	11/03/2025		S(1)		16,928	D	$99.7607(3)	207,814	D
Common Stock	11/03/2025		S(1)		29,472	D	$99.1414(4)	178,342	D
Common Stock								5,234(5)	I	By Child

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$26.15	11/03/2025		M(1)			50,000	(6)	12/01/2027	Common Stock	50,000	$0.0000	0.0000	D

Explanation of Responses:

1. The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 27, 2025.

2. Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $100.72 to $100.80, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

3. Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $99.59 to $100.53, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

4. Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $98.57 to $99.54, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

5. The reporting person disclaims beneficial ownership of the shares held by his child, and this report should not be deemed an admission that the reporting person is the beneficial owner of his child's shares for purposes of Section 16 or for any other purpose.

6. Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on December 1, 2018, the first anniversary of the date of grant.

	/s/ Susan Thompson, Attorney-in-Fact	11/04/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.